Cipher Pharmaceuticals Inc (TSE:CPH) – Investment analysts at Cormark reduced their Q1 2017 earnings estimates for shares of Cipher Pharmaceuticals in a research report issued to clients and investors on Monday. Cormark analyst D. Novak now expects that the brokerage will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.10. Cormark also issued estimates for Cipher Pharmaceuticals’ Q2 2017 earnings at $0.04 EPS, Q3 2017 earnings at $0.08 EPS and FY2017 earnings at $0.22 EPS.

A number of other brokerages have also recently issued reports on CPH. TD Securities reaffirmed a “buy” rating and set a C$7.50 price objective on shares of Cipher Pharmaceuticals in a research note on Thursday, August 11th. GMP Securities cut Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 11th.

Cipher Pharmaceuticals (TSE:CPH) opened at 5.05 on Tuesday. The firm’s market capitalization is $132.28 million. The company’s 50-day moving average price is $5.26 and its 200-day moving average price is $6.60. Cipher Pharmaceuticals has a 1-year low of $4.81 and a 1-year high of $8.18.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with's FREE daily email newsletter.